| NCT06431893 | A Phase 3 Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) | ENROLLING_BY_INVITATION | PHASE3 | 2024-04-30 | 2027-01 | 2027-01 |
| NCT06247085 | A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-12-28 | 2026-01 | 2025-12 |
| NCT05856760 | A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN | COMPLETED | PHASE2 | 2023-05-19 | 2024-10-25 | 2024-10-14 |
| NCT05003986 | Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | RECRUITING | PHASE2 | 2021-08-12 | 2027-04-12 | 2027-03-12 |
| NCT05562362 | Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension | COMPLETED | PHASE1 | 2020-06-18 | 2020-11-12 | 2020-11-12 |
| NCT03406611 | Pegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2019-01-22 | 2026-12 | 2026-06 |
| NCT03762850 | A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-12-11 | 2026-07 | 2023-08-07 |
| NCT03493685 | Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) | ACTIVE_NOT_RECRUITING | PHASE3 | 2018-04-17 | 2026-02 | 2023-03-20 |
| NCT03041116 | Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants | TERMINATED | PHASE3 | 2017-07-17 | 2019-12-30 | 2019-12-30 |
| NCT01613118 | Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis | COMPLETED | PHASE2 | 2014-03 | 2024-03-25 | 2016-06 |